TY - JOUR
T1 - Angiotensin-converting enzyme
T2 - Characteristics in human skin fibroblasts
AU - Smallridge, Robert C.
AU - Gamblin, George T.
AU - Eil, Charles
N1 - Funding Information:
From the Department of Clinical Physioiogy, Walter Reed Army Institute of Research, Washington, DC, and the Endocrinology Branch, Naval Hospital, and Uniformed Services University of the Health Sciences, Bethesda, Md. Supported in part by Project CIP #81-06-1516-00 from the Naval Medical Command, Navy Department, Washington, DC. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army, Department of the Navy, or rhe Department of Defense. Address reprint requests to Robert C. Smallridge, COL. MC. Department of Clinical Physiology, Walter Reed Army Institute 01 Research, Washington, DC 20307. This is a US government work. There are no restrictions on its use. 0026-0495/86/3510-0003$00.00/0
PY - 1986/10
Y1 - 1986/10
N2 - Angiotensin-converting enzyme, although most prominent in vascular endothelium, has been identified in numerous tissues. Recent studies have indicated that several hormones, including glucocorticoids and thyroid hormone, may affect the activity of this enzyme. In the present study, angiotensin-converting enzyme was examined in homogenates of cultured human skin fibroblasts. Angiotensin-converting enzyme activity was measured by a radiometric assay using [Glycine-1-14C] Hippuryl-l-histidyl-l-leucine (1.1 mmol/L) as substrate, and was expressed as nmol hippuric acid formed per minute/mg protein. Angiotensin-converting enzyme was identified in all five cell strains tested, and the activity observed was 0.97 ± 0.18 nmol/min/mg protein (mean ± SE). The optimum pH was between 6.9 and 7.6, and optimum temperature was 37 °C, with loss of activity of 55 °C and higher. Buffer strengh was optimized at Tris 0.025 mol/L, and 1.0 mol/L NaCl. Activity increased linearly with protein concentration and with time, and the Km = 1.14 mmol/L. The most potent inhibitor of fibroblast ACE was captopril (SQ 14,225) with an IC50 = 10-10 mol/L; other inhibitors included SQ 20,881, EDTA, and phenanthroline. Competitive substrates included angiotensin-I, substance P, and bradykinin. Four hormones, T3 (10-9-10-7 mol/L), 1,25 (OH)2D3 (10-8-10-7 mol/L), dexamethasone (10-7-10-6 mol/L), and a synthetic androgen, R1881 (10-8-10-7 mol/L) were incubated with cells for 72 hours. In all incubations, there was no significant effect on cellular ACE activity induced by any agent. Angiotensin-converting enzyme activity in serum free media was <1% of cell activity and was unaltered by hormone treatment. Human skin fibroblasts have ACE activity similar in many respects to other tissues, although several hormones failed to affect the activity of this enzyme. Recent evidence in several tissues suggests there may be local, functioning renin-angiotensin systems. The presence of ACE in skin fibroblasts may indicate that such a system is available for local regulation of cutaneous vasoconstriction.
AB - Angiotensin-converting enzyme, although most prominent in vascular endothelium, has been identified in numerous tissues. Recent studies have indicated that several hormones, including glucocorticoids and thyroid hormone, may affect the activity of this enzyme. In the present study, angiotensin-converting enzyme was examined in homogenates of cultured human skin fibroblasts. Angiotensin-converting enzyme activity was measured by a radiometric assay using [Glycine-1-14C] Hippuryl-l-histidyl-l-leucine (1.1 mmol/L) as substrate, and was expressed as nmol hippuric acid formed per minute/mg protein. Angiotensin-converting enzyme was identified in all five cell strains tested, and the activity observed was 0.97 ± 0.18 nmol/min/mg protein (mean ± SE). The optimum pH was between 6.9 and 7.6, and optimum temperature was 37 °C, with loss of activity of 55 °C and higher. Buffer strengh was optimized at Tris 0.025 mol/L, and 1.0 mol/L NaCl. Activity increased linearly with protein concentration and with time, and the Km = 1.14 mmol/L. The most potent inhibitor of fibroblast ACE was captopril (SQ 14,225) with an IC50 = 10-10 mol/L; other inhibitors included SQ 20,881, EDTA, and phenanthroline. Competitive substrates included angiotensin-I, substance P, and bradykinin. Four hormones, T3 (10-9-10-7 mol/L), 1,25 (OH)2D3 (10-8-10-7 mol/L), dexamethasone (10-7-10-6 mol/L), and a synthetic androgen, R1881 (10-8-10-7 mol/L) were incubated with cells for 72 hours. In all incubations, there was no significant effect on cellular ACE activity induced by any agent. Angiotensin-converting enzyme activity in serum free media was <1% of cell activity and was unaltered by hormone treatment. Human skin fibroblasts have ACE activity similar in many respects to other tissues, although several hormones failed to affect the activity of this enzyme. Recent evidence in several tissues suggests there may be local, functioning renin-angiotensin systems. The presence of ACE in skin fibroblasts may indicate that such a system is available for local regulation of cutaneous vasoconstriction.
UR - http://www.scopus.com/inward/record.url?scp=0023032751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023032751&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(86)90051-X
DO - 10.1016/0026-0495(86)90051-X
M3 - Article
C2 - 3020342
AN - SCOPUS:0023032751
VL - 35
SP - 899
EP - 904
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 10
ER -